5 October 2017 EMA/CVMP/617222/2017 Committee for Medicinal Products for Veterinary Use

Opinion of the Committee for Medicinal Products for Veterinary Use on the establishment of maximum residue limits Procedure no: EMEA/V/MRL/004321/FULL/0001 Name of the substance: Solvent naphtha, light aromatic Basis for the opinion Pursuant to Article 3 of Regulation (EC) No 470/2009 of 6 May 2009, Zoetis Belgium SA submitted to the European Medicines Agency on 2 October 2015 an application for the establishment of maximum residue limits for solvent naphtha, light aromatic in all food producing species. On 18 February 2016, the Committee for Medicinal Products for Veterinary Use adopted a list of questions to be addressed by the applicant. The response to the list of questions was submitted on 13 March 2017.

Recommendation The Committee, having considered the application, and having evaluated the response to the list of questions, recommends by consensus the inclusion of solvent naphtha, light aromatic in table 1 of the Annex to Regulation (EU) No 37/2010 as follows: Pharmacologically active substance

Marker residue

Animal species

MRLs

Target tissues

Other provisions

Therapeutic classification

Solvent naphtha, light aromatic, with

NOT APPLICABLE

All food producing species

No MRL required

NOT APPLICABLE

For cutaneous use only.

NO ENTRY

cumene concentrati on not exceeding 2.5%, and benzene concentrati on not exceeding 0.0002% 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5545 Send a question via our website www.ema.europa.eu/contact

Only at volume not exceeding 15 μl solvent naphtha/kg bw.

An agency of the European Union

The Norwegian CVMP member agrees with the above-mentioned recommendation of the Committee. The scientific conclusions of the Committee are presented in the European public MRL assessment report (EPMAR), provided in Annex I of this opinion. The present opinion is forwarded to the European Commission and to the applicant together with its appendices.

Opinion of the Committee for Medicinal Products for Veterinary Use on the establishment of maximum residue limits EMA/CVMP/617222/2017

Page 2/2

Annex I European public MRL assessment report (EPMAR)

CVMP opinion for solvent naphtha, light aromatic - European ...

Oct 5, 2017 - Pursuant to Article 3 of Regulation (EC) No 470/2009 of 6 May 2009, Zoetis Belgium SA submitted to the. European Medicines Agency on 2 ...

77KB Sizes 0 Downloads 224 Views

Recommend Documents

Solvent naphtha, light aromatic - Summary opinion of the CVMP on the ...
Oct 6, 2017 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union. Telephone ... Animal species. MRLs. Target tissues. Other provisions. Therapeutic classification. Solvent naphtha, light aromati

CVMP opinion on fluazuron - European Medicines Agency - Europa EU
Oct 5, 2017 - Veterinary Use on the establishment of maximum residue limits. Procedure no: EMEA/V/MRL/003471/EXTN/0002. Name of the substance: ...

Diflubenzuron - Summary opinion of the CVMP on the establishment ...
Mar 15, 2018 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union ... Animal species. MRLs. Target tissues. Other provisions. Therapeutic classification. Diflubenzuron Diflubenzuron. Salmonidae.

Alarelin - Summary opinion of the CVMP on the establishment of ...
On 12 April 2017, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted an opinion2 recommending the inclusion of alarelin in all food ...

Work Plan for the CVMP Pharmacovigilance Working Party - European ...
Dec 8, 2016 - regulatory measures in relation to risk management. ... Master Plan endorsed by the European Medicines Agency Management Board and ...

Divergent position on a CVMP opinion on the establishment of ...
Reading summary reports and the assessment report that was prepared for the current procedure, the following can be summarised: •. We do not have accessible any relevant scientific information concerning the behaviour and fate of fluazuron in milk,

Divergent position on a CVMP opinion on the establishment of ...
The CVMP has estimated the safe level based on a mathematic calculation only (even if the conclusion is that exposure does not represent a sizable part of the ...

CVMP Risk Management Strategy - European Medicines Agency
Feb 16, 2017 - Scientific data exist that demonstrate replication competent RD114 ... A risk assessment consists of the identification of hazards and the analysis and evaluation of risks ...... interpretation of a positive signal maybe equivocal.

Work plan for the CVMP Scientific Advice Working Party - European ...
European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 7 December 2017. EMA/CVMP/SAWP/574285/2017. Committee for Medicinal Products for Veterinary Use (CVMP). Work plan for the CVMP Scientific Advice Working

Work plan for the CVMP Immunologicals Working Party - European ...
European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 7 December 2017. EMA/CVMP/IWP/347865/2017. Committee for Medicinal Products for Veterinary Use (CVMP). Work plan for the CVMP Immunologicals Working Part

CVMP Risk Management Strategy - European Medicines Agency
Feb 16, 2017 - An agency of the European Union. Telephone +44 ... European Medicines Agency, 2017. ...... Jin-Hoi Kim, Jae-Wook Oh, Kunho Seo. Virology ...

04 - Minutes CVMP April 2018 - for publication - European Medicines ...
May 23, 2018 - 7.10 Joint CVMP/CHMP Working Group on the application of the 3Rs (J3RsWG) .... SK. Judita Hederová. Full involvement. UK. Helen Jukes.

Work plan for the CVMP Pharmacovigilance Working Party - European ...
recommendations for regulatory measures in relation to risk management. ... and humans to veterinary medicinal products (EMA/CVMP/10418/2009). Action:.

Work plan for the CVMP Safety Working Party - European Medicines ...
EMA/CVMP/SWP/278493/2017. Committee for Medicinal Products for Veterinary Use (CVMP). Work plan for the CVMP Safety Working Party (SWP-V). 2018. Chairpersons. Status. Chair: E. Lander Persson. Vice-chair: S. Scheid. Adopted by CVMP in December 2017.

Eprinomectin summary opinion - European Medicines Agency
Nov 9, 2017 - Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555. Send a question via our website www.ema.europa.eu/contact. © European ...

Porcine prolactin summary opinion - European Medicines Agency
Nov 9, 2017 - Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555. Send a question via our website www.ema.europa.eu/contact. © European ...

Paromomycin summary opinion - European Medicines Agency
Feb 15, 2018 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union ... Animal species. MRLs. Target tissues. Other provisions. Therapeutic classification. Paromomycin. Paromomycin All food produc

4029 WIN - Organisation of CVMP Working Party meetings - European ...
(laptop/desktop) on the MMD login page. Please remember to use the Table of Content document .... Page 9/14. Annex I. Lists of permanent agenda points. AWP.

Minutes of the October 2017 CVMP meeting - European Medicines ...
Nov 7, 2017 - The minutes of the September 2017 meeting were adopted with no amendments. v. Topics for rapporteur's meetings, break-out sessions and ...

CVMP strategy on antimicrobials 2016-2020 - European Medicines ...
Oct 6, 2016 - Summary of the CVMP strategy on antimicrobials 2016-2020 ..... antimicrobial VMPs are aimed at reducing the regulatory uncertainty that acts.

Procedural advice on re-examination of CVMP opinions - European ...
Nov 9, 2017 - be based only on the scientific data available when the Committee ... Article 34(1) and (2) of Regulation (EC) No 726/2004 shall apply to the ...

4029 WIN - Organisation of CVMP Working Party meetings - European ...
WPs/For secretariats). Send an email to the members of the relevant WP (cc the WP inbox, if ... following link: https://access.ema.europa.eu/sslvpn. You will find ...

Minutes of the September 2017 CVMP meeting - European Medicines ...
European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 3 October 2017. EMA/CVMP/659549/2017. Committee for ... Minutes of the 5-7 September 2017 meeting. Chair: D. Murphy ..... shellfish diseases held on 4-8

Agenda of January 2018 CVMP meeting - European Medicines Agency
Jan 16, 2018 - framework of Regulation (EC) No 1049/2001 on access to documents because they are subject to on- going procedures for ... Co-rapp: C. Muñoz. For decision: Need for oral explanation. For adoption: Scientific overview and list of outsta